Press Release

GRANULES Date: July 21, 2026 National Stock Exchange of India Limited BSE Limited Symbol: NSE: GRANULES: BSE: 532482 Dear Sir, Sub: Press Release to the Analysts/Investors We refer to the unaudited financial results for the first quarter of the FY 2026-2027, submitted to you today, i.e., on July 21, 2026. We are now enclosing the press release in this regard to the Analysts/Investors, which is also being uploaded on our website. This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the above information on record. For GRANULES INDIA LIMITED CHAITANYA TUMMALA (COMPANY SECRETARY & COMPLIANCE OFFICER) REGISTERED OFFICE Granules India Limited CIN: L24110TG1991PLC012471 15 Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad - 500084, Telangana, India Contact Us: Tel: +91 40 69043500 | Fax: +91-40-23115145 | mail@granulesindia.com www.granulesindia.com Press Release for Immediate Release Q1FY27 Revenue from operations at INR 14,768 Mn up 22% YoY, EBITDA at INR 3,389 Mn up 37% YoY, PBT before Exceptional Item at INR 2,404 Mn up 41% YoY, PAT at INR 1,800 Mn up 60% YoY. Hyderabad, India, July 21, 2026: Granules In dia Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended June 30, 2026. Financial Summary (All numbers in INR Mn) QUARTERLY CONSOLIDATED Growth Growth Q1FY27 Q4FY26 Q1FY26 FINANCIALS (QoQ) (YoY) Revenue from Operations 14,768 14,706 0% 12,101 22% EBITDA 3,389 3,521 -4% 2,467 37% EBITDA % 23% 24% 20% PBT Before Exceptional Item 2,404 2,464 -2% 1,704 41% Exceptional Item / (Income) 0 (159) 259 PAT 1,800 2,016 -11% 1,126 60% PAT % 12% 14% 9% Financial and Business Summary for Q1FY27 ▪ Revenue from Operations of Q1FY27 stood at INR 14,768 Mn, a growth of 22% YoY, Revenue share from the North America is 72% in Q1FY27 as compared to 77% in Q1FY26 and from the Europe is 16% in Q1FY27 as compared to 13% in Q1FY26. ▪ Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides CDMO contribute 74%, 13%, 9% and 4% of revenue from operations respectively for Q1FY27. ▪ ROCE improved to 18.0% in Q1FY27 from 17.6% in FY26. ▪ Net debt stood at INR 1,012 Mn, a reduction of INR 8,467 Mn from Q1FY26 and Net debt to EBITDA at 0.07x Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “Q1 FY27 marks an important step forward for Granules India as the foundations strengthened during FY26 begin to translate into greater execution confidence, strategic clarity and business resilience. Our focus remains firmly on regulatory and quality excellence, portfolio transformation toward complex and differentiated products, geographic and customer diversification and scaling new growth engines. While external cost pressures and supply chain volatility require continuous management for next couple of quarters, we are continuing to invest in R&D largely towards Complex Gx, digitalization, operational excellence, sustainability and talent to support long-term value creation. With a stronger organization, a more balanced portfolio and clear strategic priorities, we remain confident in Granules’ ability to deliver sustainable growth for all stakeholders.” About Granules India Ltd. (BSE: 532482, NSE: GRANULES) Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 7 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL. Safe Harbour This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward- looking statements, whether as a result of new information, future events, or otherwise. Contacts: Granules IR Desk Chaitanya Tummala investorrelations@granulesindia.com Company Secretary chaitanya.tummala@granulesindia.com